The US Food and Drug Administration (FDA) has approved dexmedetomidine (Igalmi) sublingual film for at-home treatment of acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults, Teva Pharmaceuticals announced on November 16, 2026.¹
Dexmedetomidine is a highly selective α2-adrenergic receptor agonist. Before this approval, it could only be given under a healthcare provider’s supervision.¹ Until now, no FDA-approved treatment was indicated for patients to take themselves at home during an agitation episode. According to Teva, agitation affects 25% to 40% of patients with these conditions, and up to 21% of episodes result in an emergency department visit or hospitalization.¹
“For people living with schizophrenia, schizoaffective disorder, or bipolar disorder, agitation can be disruptive and challenging for themselves and for the caregivers who support them,” said Chris Fox, executive vice president, US Commercial and head of Innovative Franchise at Teva, in a statement.1 “With the first FDA-approved, at-home treatment for agitation associated with these conditions, we have an opportunity to bring an important treatment option into a setting where patients often need it.”
Dexmedetomidine Safety and Tolerability in SERENITY At-Home
Teva submitted the supplemental New Drug Application (sNDA) on January 14, 2026, as an addition to the original application for supervised use.¹ Teva acquired the product in late October 2026 and will announce commercialization plans for at-home use at a later date.¹
SERENITY At-Home was a randomized, double-blind, placebo-controlled, 12-week phase 3 trial of sublingual dexmedetomidine in adults with agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.¹,2 Participants gave themselves the drug outside a supervised healthcare setting. The trial met its primary endpoint of safety and tolerability in the at-home setting, according to Teva.¹
In total, 102 patients treated 1160 agitation episodes with dexmedetomidine during the study.¹,² Tolerability stayed consistent with repeat dosing across the 12-week period, and no patients stopped treatment because of tolerability.¹
Dexmedetomidine Efficacy and Adverse Events Across SERENITY Trials
The most common adverse events in SERENITY At-Home (≥ 5% and greater than placebo) were somnolence, dry mouth, dizziness, and oral paresthesia or oral hypoesthesia.¹ Teva said these events were consistent with the known pharmacology of dexmedetomidine in the healthcare-supervised setting.¹
The efficacy evidence comes from the pivotal SERENITY I and II trials.1 Across both studies, dexmedetomidine reduced the Positive and Negative Syndrome Scale-Excited Component (PEC) total score by approximately 9.6 points at 2 hours after administration, compared with approximately 4.9 points with placebo.¹
Teva reported statistically significant reductions versus placebo, with treatment effects seen as early as 20 minutes at some doses. The safety information warns of hypotension, orthostatic hypotension, and bradycardia, and advises patients to drink fluids, sit or lie down after dosing, and rise slowly. Before prescribing, clinicians should review cardiac history, age ≥ 65 years, liver problems, and any concurrent antihypertensive, opioid, or sedating medications.¹
“Innovation in neuroscience is about discovering new medicines and also about rethinking when, where and how treatment can be delivered,” said Eric Hughes, MD, PhD, executive vice president, Global R&D and chief medical officer at Teva, in the statement.1 “The ability to treat agitation symptoms when they start gives patients and caregivers an important new way to manage these episodes.”
References
U.S. FDA approves IGALMI as first at-home acute treatment for agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults. Teva Pharmaceuticals. Published November 16, 2026. Accessed November 16, 2026. https://www.tevausa.com/en/us/news-and-media/press-releases
Citrome L, Rajachandran L, Risinger R, et al. BXCL501 (sublingual dexmedetomidine) for treatment of agitation associated with bipolar disorder or schizophrenia in the home setting: a phase 3 study. Poster. 2025. Accessed November 16, 2026. https://www.sec.gov/Archives/edgar/data/1720893/000110465925108840/tm2530721d1_ex99-1.htm